Evoke Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVOK research report →
About the company
Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials.
- CEO
- Mark A. Kowieski
- IPO
- 2013
- Employees
- 3
- HQ
- Solana Beach, CA, US
Price Chart
- Market Cap
- $18.95M
- P/E
- -4.62
- P/S
- 1.31
- P/B
- 8.37
- EV/EBITDA
- -2.64
- Div Yield
- 0.00%
- Gross Margin
- 97.02%
- Op Margin
- -35.99%
- Net Margin
- -36.23%
- ROE
- -101.40%
- ROIC
- -61.27%
- Revenue
- $10.25M · 97.84%
- Net Income
- $-5,352,194 · 31.31%
- EPS
- $-2.81 · 89.95%
- Op Income
- $-5,204,137
- FCF YoY
- -9.50%
- 52W High
- $11.00
- 52W Low
- $1.94
- 50D MA
- $8.52
- 200D MA
- $5.04
- Beta
- -0.14
- Avg Volume
- 100.37K
Get TickerSpark's AI analysis on EVOK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 148,153 |
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 433,962 |
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 117,019 |
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 117,019 |
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 158,531 |
| Dec 17, 25 | Nantahala Capital Management, LLC | other | 250,627 |
| Dec 17, 25 | PYSZCZYMUKA GREG | sell | 5,833 |
| Dec 17, 25 | PYSZCZYMUKA GREG | sell | 1,155 |
| Dec 17, 25 | Smeal Benjamin C. | sell | 5,833 |
| Dec 17, 25 | Smeal Benjamin C. | sell | 1,125 |
Our EVOK coverage
Recent articles, reports, and earnings notes.
No research on EVOK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EVOK report →Similar companies
Peers in the same neighborhood.